$NVO

A study in Lancet Psychiatry found GLP-1 receptor agonists reduced psychiatric hospitalizations in schizophrenia patients with type 2 diabetes. Novo Nordisk (NVO), a leader in GLP-1 therapies, has a 4.38% dividend yield, low payout ratio, and strong dividend growth. The company's GF Score is 75, indicating solid profitability and financial strength. NVO is trading at a 61.1% discount to its intrinsic value, according to GuruFocus.

Novo Nordisk reported 2025 revenue of $46.3B (+6.4% YoY) and net income of $15.3B (33.1% margin). It faces competition and pricing pressures. AbbVie's Skyrizi and Rinvoq drove 42% of 2025 sales, but it faces pricing pressures and litigation. Both companies have growth prospects and challenges. Analysts debate their long-term outlooks.

Pennsylvania sued 17 pharma companies and PBMs, including Eli Lilly, Sanofi, and Novo Nordisk, for allegedly colluding to raise insulin prices by over 1,000% since the mid-2000s. The lawsuit claims this harmed 1.3 million diabetics in the state, forcing many to ration insulin. The state seeks restitution and penalties under consumer protection laws.

Eli Lilly (LLY) has seen significant growth due to its GLP-1 weight-loss drugs, Mounjaro and Zepbound, with a market cap of $1.1 trillion. Competition is intensifying, with companies like Novo Nordisk (NVO), Viking Therapeutics (VKTX), Amgen (AMGN), and Regeneron (REGN) developing new treatments. GLP-1 drugs are also impacting consumer spending, affecting companies like General Mills (GIS). Absci (ABSI) and Telescope Innovations (TELIF) are leveraging AI to aid drug development.

Novo Nordisk (NVO) and Eli Lilly (LLY) presented research at the ARDD conference suggesting their GLP-1 drugs may slow aging by 2-4 years. NVO's semaglutide and LLY's tirzepatide showed improvements in biological aging markers, but studies were not peer-reviewed and focused on obesity/diabetes patients.

Novo Nordisk seeks Korean insurance coverage for Wegovy to compete with Eli Lilly's Mounjaro and upcoming Hanmi Pharmaceutical's Eppe. Wegovy's market share is 13.2% vs. Mounjaro's 86.7%. Approval could lower costs and boost access.

The HSE in Ireland reimburses Saxenda for weight loss and Ozempic for diabetes. Mounjaro's reimbursement is under review. Novo Nordisk and Eli Lilly manufacture these GLP-1 drugs. Cost-effectiveness and clinical criteria determine availability. Eli Lilly has offered a price reduction for Mounjaro, potentially making it cost-effective.

BMO Capital reduced its price target for Novo Nordisk (NYSE: NVO) to $40 from $47, citing challenges in Ozempic revenue due to market share decline and tough year-over-year comparisons. The stock is down 21.5% year-to-date. Novo Nordisk recently entered a licensing deal with Nanexa and plans a potential NYSE listing. Morgan Stanley downgraded the stock to Underweight.

Novo Nordisk repurchased 37.8 million B shares from Feb. 4 to Oct. 9, 2026, spending DKK 10.56 billion. The company plans to repurchase up to DKK 15 billion in shares within a 12-month period starting Feb. 4, 2026. As of Oct. 9, it owns 51.9 million B shares as treasury shares.

Lawsuits allege Novo Nordisk's GLP-1 drugs, like Ozempic, cause serious harm, including optic neuropathy. The FDA has received over 1,000 reports of optic neuropathy linked to GLP-1s since 2024. Novo Nordisk disputes the claims, citing rare occurrences in clinical trials. The FDA is assessing the risks. Eli Lilly also faces lawsuits over its GLP-1 drugs, Mounjaro and Zepbound.